IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 13, 2017, Imprimis Pharmaceuticals, Inc. held its 2017
Annual Meeting of Stockholders (the Annual Meeting) at the San
Diego Marriott Del Mar Hotel, 11966 El Camino Real, San Diego,
California 92130. The number of shares of common stock entitled
to vote at the Annual Meeting was 19,965,415. The number of
shares of common stock present or represented by valid proxy at
the Annual Meeting was 15,025,849. All matters submitted to a
binding vote of stockholders at the Annual Meeting were approved.
The number of votes cast for and against, and the number of
abstentions and broker non-votes with respect to the matters
voted upon at the Annual Meeting, are set forth below:
Proposal 1: Election of Directors
Stockholders voted to elect to the Board of Directors the five
(5) director nominees named in the accompanying proxy statement
to serve until the 2018 annual meeting of stockholders and until
their successors are duly elected and qualified. The results of
the voting were:
| Directors | For | Withheld | Broker Non-Vote | |||||||||
| Stephen G. Austin | 7,319,390 | 1,793,002 | 5,913,457 | |||||||||
| Mark L. Baum | 8,383,693 | 728,699 | 5,913,457 | |||||||||
| Robert J. Kammer | 7,362,623 | 1,749,769 | 5,913,457 | |||||||||
| Richard L. Lindstrom | 7,296,997 | 1,815,395 | 5,913,457 | |||||||||
| Anthony J. Principi | 8,086,228 | 1,026,164 | 5,913,457 | |||||||||
Proposal 2: Ratification of Auditors
Stockholders ratified the selection of KMJ Corbin and Company,
LLP as the Companys independent registered public accounting firm
for the fiscal year ending December 31, 2017. The results of the
voting were:
| For | Against | Abstain | Broker Non-Vote | |||||||||||
| 14,736,566 | 167,394 | 121,889 | – | |||||||||||
Proposal 3: Approval of 2017 Incentive Plan
Stockholders approved the 2017 Incentive Stock and Awards Plan
(the 2017 Incentive Plan). The forms of award agreements to be
used in connection with the 2017 Incentive Plan are attached
hereto as Exhibits 10.1 through 10.4 and are incorporated herein
by reference. The results of the voting were:
| For | Against | Abstain | Broker Non-Vote | |||||||||||
| 6,544,464 | 2,405,375 | 162,553 | 5,913,457 | |||||||||||
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 10.1 |
Imprimis Pharmaceuticals Inc. 2017 Incentive Plan Form of Incentive Stock Option Agreement |
|
| 10.2 |
Imprimis Pharmaceuticals Inc. 2017 Incentive Plan Form of Non-Statutory Stock Option Agreement |
|
| 10.3 |
Imprimis Pharmaceuticals Inc. 2017 Incentive Plan Form of Restricted Stock Award Agreement |
|
| 10.4 |
Imprimis Pharmaceuticals Inc. 2017 Incentive Plan Form of Restricted Stock Unit Agreement |
About IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY)
Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.